Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Distinct SNP combinations confer susceptibility to urinary bladder cancer in smokers and non-smokers.

Schwender H, Selinski S, Blaszkewicz M, Marchan R, Ickstadt K, Golka K, Hengstler JG.

PLoS One. 2012;7(12):e51880. doi: 10.1371/journal.pone.0051880. Epub 2012 Dec 20. Erratum in: PLoS One. 2015;10(9):e0137937.

2.

Genome-wide interaction study of smoking and bladder cancer risk.

Figueroa JD, Han SS, Garcia-Closas M, Baris D, Jacobs EJ, Kogevinas M, Schwenn M, Malats N, Johnson A, Purdue MP, Caporaso N, Landi MT, Prokunina-Olsson L, Wang Z, Hutchinson A, Burdette L, Wheeler W, Vineis P, Siddiq A, Cortessis VK, Kooperberg C, Cussenot O, Benhamou S, Prescott J, Porru S, Bueno-de-Mesquita HB, Trichopoulos D, Ljungberg B, Clavel-Chapelon F, Weiderpass E, Krogh V, Dorronsoro M, Travis R, Tjønneland A, Brenan P, Chang-Claude J, Riboli E, Conti D, Gago-Dominguez M, Stern MC, Pike MC, Van Den Berg D, Yuan JM, Hohensee C, Rodabough R, Cancel-Tassin G, Roupret M, Comperat E, Chen C, De Vivo I, Giovannucci E, Hunter DJ, Kraft P, Lindstrom S, Carta A, Pavanello S, Arici C, Mastrangelo G, Karagas MR, Schned A, Armenti KR, Hosain GM, Haiman CA, Fraumeni JF Jr, Chanock SJ, Chatterjee N, Rothman N, Silverman DT.

Carcinogenesis. 2014 Aug;35(8):1737-44. doi: 10.1093/carcin/bgu064. Epub 2014 Mar 24.

3.

GSTA1, GSTM1, GSTP1, and GSTT1 polymorphisms and susceptibility to smoking-related bladder cancer: a case-control study.

Matic M, Pekmezovic T, Djukic T, Mimic-Oka J, Dragicevic D, Krivic B, Suvakov S, Savic-Radojevic A, Pljesa-Ercegovac M, Tulic C, Coric V, Simic T.

Urol Oncol. 2013 Oct;31(7):1184-92. doi: 10.1016/j.urolonc.2011.08.005.

PMID:
24075358
4.

Rs11892031[A] on chromosome 2q37 in an intronic region of the UGT1A locus is associated with urinary bladder cancer risk.

Selinski S, Lehmann ML, Blaszkewicz M, Ovsiannikov D, Moormann O, Guballa C, Kress A, Truss MC, Gerullis H, Otto T, Barski D, Niegisch G, Albers P, Frees S, Brenner W, Thüroff JW, Angeli-Greaves M, Seidel T, Roth G, Volkert F, Ebbinghaus R, Prager HM, Bolt HM, Falkenstein M, Zimmermann A, Klein T, Reckwitz T, Roemer HC, Hartel M, Weistenhöfer W, Schöps W, Rizvi SA, Aslam M, Bánfi G, Romics I, Ickstadt K, Hengstler JG, Golka K.

Arch Toxicol. 2012 Sep;86(9):1369-78. doi: 10.1007/s00204-012-0854-y. Epub 2012 Apr 25.

PMID:
22532026
5.

Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction.

Lacombe L, Fradet V, Lévesque É, Pouliot F, Larue H, Bergeron A, Hovington H, Caron A, Nguile-Makao M, Harvey M, Fradet Y, Guillemette C.

Cancer Prev Res (Phila). 2016 Feb;9(2):189-95. doi: 10.1158/1940-6207.CAPR-15-0069. Epub 2015 Dec 8.

6.

GSTP1 gene Ile105Val polymorphism causes an elevated risk for bladder carcinogenesis in smokers.

Pandith AA, Lateef A, Shahnawaz S, Hussain A, Malla TM, Azad N, Shehjar F, Salim M, Shah ZA.

Asian Pac J Cancer Prev. 2013;14(11):6375-8.

7.

Application of multi-SNP approaches Bayesian LASSO and AUC-RF to detect main effects of inflammatory-gene variants associated with bladder cancer risk.

de Maturana EL, Ye Y, Calle ML, Rothman N, Urrea V, Kogevinas M, Petrus S, Chanock SJ, Tardón A, García-Closas M, González-Neira A, Vellalta G, Carrato A, Navarro A, Lorente-Galdós B, Silverman DT, Real FX, Wu X, Malats N.

PLoS One. 2013 Dec 31;8(12):e83745. doi: 10.1371/journal.pone.0083745. eCollection 2013.

8.

Susceptibility to urinary bladder cancer: relevance of rs9642880[T], GSTM1 0/0 and occupational exposure.

Golka K, Hermes M, Selinski S, Blaszkewicz M, Bolt HM, Roth G, Dietrich H, Prager HM, Ickstadt K, Hengstler JG.

Pharmacogenet Genomics. 2009 Nov;19(11):903-6. doi: 10.1097/FPC.0b013e328331b554.

PMID:
19801959
9.

Cumulative effect of genome-wide association study-identified genetic variants for bladder cancer.

Wang M, Chu H, Lv Q, Wang L, Yuan L, Fu G, Tong N, Qin C, Yin C, Zhang Z, Xu J.

Int J Cancer. 2014 Dec 1;135(11):2653-60. doi: 10.1002/ijc.28898. Epub 2014 Apr 25.

10.

Comparing the joint effect of arsenic exposure, cigarette smoking and risk genotypes of vascular endothelial growth factor on upper urinary tract urothelial carcinoma and bladder cancer.

Wang YH, Yeh SD, Wu MM, Liu CT, Shen CH, Shen KH, Pu YS, Hsu LI, Chiou HY, Chen CJ.

J Hazard Mater. 2013 Nov 15;262:1139-46. doi: 10.1016/j.jhazmat.2012.08.056. Epub 2012 Sep 7.

PMID:
23009795
11.

N-acetyltransferase 2 gene polymorphism as a biomarker for susceptibility to bladder cancer in Bangladeshi population.

Hosen MB, Islam J, Salam MA, Islam MF, Hawlader MZ, Kabir Y.

Asia Pac J Clin Oncol. 2015 Mar;11(1):78-84. doi: 10.1111/ajco.12291. Epub 2014 Nov 6.

PMID:
25376209
12.

NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.

García-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Castaño-Vinyals G, Yeager M, Welch R, Chanock S, Chatterjee N, Wacholder S, Samanic C, Torà M, Fernández F, Real FX, Rothman N.

Lancet. 2005 Aug 20-26;366(9486):649-59.

13.

Polymorphic deletions of the GSTT1 and GSTM1 genes and susceptibility to bladder cancer.

Salinas-Sánchez AS, Sánchez-Sánchez F, Donate-Moreno MJ, Rubio-del-Campo A, Gimenez-Bachs JM, Lorenzo-Romero JG, Serrano-Oviedo L, Escribano J.

BJU Int. 2011 Jun;107(11):1825-32. doi: 10.1111/j.1464-410X.2010.09683.x. Epub 2010 Oct 13.

14.
15.

Analysis of variants in DNA damage signalling genes in bladder cancer.

Choudhury A, Elliott F, Iles MM, Churchman M, Bristow RG, Bishop DT, Kiltie AE.

BMC Med Genet. 2008 Jul 18;9:69. doi: 10.1186/1471-2350-9-69.

16.

Genome-wide association study identified SNP on 15q24 associated with bladder cancer risk in Japanese population.

Matsuda K, Takahashi A, Middlebrooks CD, Obara W, Nasu Y, Inoue K, Tamura K, Yamasaki I, Naya Y, Tanikawa C, Cui R, Figueroa JD, Silverman DT, Rothman N, Namiki M, Tomita Y, Nishiyama H, Kohri K, Deguchi T, Nakagawa M, Yokoyama M, Miki T, Kumon H, Fujioka T, Prokunina-Olsson L, Kubo M, Nakamura Y, Shuin T.

Hum Mol Genet. 2015 Feb 15;24(4):1177-84. doi: 10.1093/hmg/ddu512. Epub 2014 Oct 3.

17.

Study on bladder cancer susceptibility and genetic polymorphisms of XPC, XPG, and CYP in smokers and non-smokers.

Wen H, Feng CC, Fang ZJ, Xia GW, Jiang HW, Xu G, Huang XD, Ding Q.

Actas Urol Esp. 2013 May;37(5):259-65. doi: 10.1016/j.acuro.2012.04.007. Epub 2012 Dec 13. English, Spanish.

PMID:
23246108
18.

Genetic polymorphism of glutathione S-transferases M1 and T1 as a risk factor in lung and bladder cancers.

Salagovic J, Kalina I, Stubna J, Habalová V, Hrivnák M, Valanský L, Kohút A, Biros E.

Neoplasma. 1998;45(5):312-7.

PMID:
9921921
19.

An association between hOGG1 Ser326Cys polymorphism and the risk of bladder cancer in non-smokers: a meta-analysis.

Ji C, Liu Z, Chen H, Guo H, Liu C.

BMC Cancer. 2012 Aug 2;12:335. doi: 10.1186/1471-2407-12-335.

20.

Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes.

Wu X, Gu J, Grossman HB, Amos CI, Etzel C, Huang M, Zhang Q, Millikan RE, Lerner S, Dinney CP, Spitz MR.

Am J Hum Genet. 2006 Mar;78(3):464-79. Epub 2006 Jan 31.

Supplemental Content

Support Center